Table of Content

1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Approach
2.2. Process Of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from The Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.1.1. Growing Therapeutic Applications of Pharmacogenomic Biomarkers Supporting Market Growth
4.2.1.2. Increasing Adoption of Personalized Medicines Driving the Demand for Pharmacogenomics
4.2.1.3. Rising Geriatric Population and Chronic Disease Prevalence Boosting Pharmacogenomic Research and Testing
4.2.1.4. The U.S. FDA’s And EMA’s Recommendations for Using Pharmacogenomic Data in Drug Discovery & Development Accelerating Market Expansion
4.2.1.5. Growing Awareness Regarding Adverse Drug Reactions (ADRs) Generating Opportunities for Market Players
4.2.1.6. Low Awareness About Pharmacogenomics and Personalized Medicine to Remain a Major Challenge for Market Stakeholders
4.2.1.7. Lack Of Reimbursements for Genetic Testing and Precision Medicine Impacting Market Growth
4.2.2. Factors Analysis
4.3. Key Trends
4.3.1. Declining Costs of Sequencing Making Pharmacogenomic Testing More Affordable
4.3.2. Increasing Potential of AI In Pharmacogenomics
4.4. Regulatory Analysis
4.4.1. U.S
4.4.2. Canada
4.4.3. Europe
4.4.4. China
4.4.5. Japan
4.4.6. India
4.4.7. Latin America
4.4.8. Middle East & Africa
4.5. Pricing Analysis
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Buyers
4.6.2. Bargaining Power of Suppliers
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Degree Of Competition

5. Pharmacogenomics Market Assessment?by Offering
5.1. Overview
5.2. Consumables
5.3. Instruments
5.4. Software & Services

6. Pharmacogenomics Market Assessment?by Technology
6.1. Overview
6.2. Polymerase Chain Reaction (PCR)
6.3. Sequencing
6.4. Microarray
6.5. Mass Spectrometry
6.6. Electrophoresis
6.7. Other Technologies

7. Global Pharmacogenomics Market Assessment?by Application
7.1. Overview
7.2. Oncology
7.3. Mental Health
7.4. Infectious Diseases
7.5. Cardiology
7.6. Neurological Disorders
7.7. Other Applications

8. Pharmacogenomics Market Assessment?by End User
8.1. Overview
8.2. Hospitals & Diagnostic Laboratories
8.3. Academic & Research Institutes
8.4. Other End Users

9. Pharmacogenomics Market Assessment?by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest Of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest Of Asia-Pacific
9.5. Latin America
9.6. Middle East & Africa

10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Ranking (2023)
10.5.1. Thermo Fisher Scientific, Inc. (U.S.)
10.5.2. Illumina, Inc. (U.S.)
10.5.3. Danaher Corporation (U.S.)
10.5.4. F. Hoffmann-La Roche Ltd. (Switzerland)

11. Company Profiles (Business Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)
11.1. F. Hoffmann La-Roche Ag
11.2. Thermo Fisher Scientific, Inc.
11.3. Illumina, Inc.
11.4. Danaher Corporation
11.5. Agilent Technologies, Inc.
11.6. Qiagen N.V.
11.7. Abbott Laboratories
11.8. Bio-Rad Laboratories, Inc.
11.9. PerkinElmer, Inc.
11.10. Pacific Biosciences of California, Inc.
(Note: SWOT Analysis of Top 5 Companies Will Be Provided)

12. Appendix
12.1. Available Customization
12.2. Related Reports



List of Figures

Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Pharmacogenomics Market, by Offerings, 2024 Vs. 2031 (USD Million)
Figure 8 Global Pharmacogenomics Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 9 Global Pharmacogenomics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 10 Global Pharmacogenomics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 11 Global Pharmacogenomics Market, by Geography
Figure 12 Impact Analysis of Market Dynamics
Figure 13 Percentage Share of U.S. FDA-Approved PGx-Labeled Drugs, by Application (As of June 2023)
Figure 14 U.S.: Number of Personalized Medicines on The Market, 2008-2020
Figure 15 Molecular and Cell-Based Therapies (As a Percentage of Total FDA-Approved Therapies), 2015-2021
Figure 16 Global Estimated Number of New Cancer Cases, 2020-2040 (In Million)
Figure 17 Genome Sequencing Costs, 2010–2022 (USD)
Figure 18 USFDA Regulatory Pathways for Pharmacogenomics Products
Figure 19 EU Regulatory Pathway - IVDR 2017/746
Figure 20 China: Medical Device Classification and Pre-Market Requirements for IVD Devices
Figure 21 Porter’s Five Forces Analysis
Figure 22 Global Pharmacogenomics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 23 Global Estimated Number of New Cancer Cases (2020-2040) (Million)
Figure 24 Global Pharmacogenomics Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 25 Global Pharmacogenomics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 26 Estimated Number of New Cancer Cases, 2020 Vs. 2040
Figure 27 Global Pharmacogenomics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 28 Global Pharmacogenomics Market Assessment, by Country/Region, 2024–2031 (USD Million)
Figure 29 North America: Pharmacogenomics Market Snapshot
Figure 30 Precision Medicine Research Funding To NIH, 2018-2024 (USD Million)
Figure 31 Europe: Pharmacogenomics Market Snapshot
Figure 32 Germany: Estimated Number of New Cancer Cases, 2020-2035 (In Thousand)
Figure 33 France: Total Number of People with Dementia, 2018-2050 (In Thousands)
Figure 34 Asia-Pacific: Pharmacogenomics Market Snapshot
Figure 35 Key Growth Strategies Adopted by Leading Market Players (2020-2023)
Figure 36 Pharmacogenomics Market: Competitive Benchmarking, by Offering
Figure 37 Pharmacogenomics Market: Competitive Benchmarking, by Region
Figure 38 Competitive Dashboard: Pharmacogenomics Market
Figure 39 Global Pharmacogenomics Market Ranking, by Key Players (2023)
Figure 40 F. Hoffmann La-Roche Ltd.: Financial Snapshot (2022)
Figure 41 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
Figure 42 Illumina, Inc.: Financial Overview (2022)
Figure 43 Danaher Corporation: Financial Overview (2022)
Figure 44 Agilent Technologies, Inc.: Financial Snapshot (2023)
Figure 45 Qiagen N.V.: Financial Snapshot (2022)
Figure 46 Abbott Laboratories: Financial Overview (2022)
Figure 47 Bio-Rad Laboratories, Inc.: Financial Overview (2022)
Figure 48 PerkinElmer, Inc.: Financial Overview (2022)
Figure 49 Pacific Biosciences of California, Inc.: Financial Overview (2022)